Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis - Wikidata - awgldk - TriplyDB

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

http://www.wikidata.org/entity/Q57788650

about

Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review What does an adult rheumatologist need to know about juvenile idiopathic arthritis?Advances in the treatment of polyarticular juvenile idiopathic arthritis Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.Predictors of response to methotrexate in juvenile idiopathic arthritis.Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type.Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Contrast-enhanced MRI features in the early diagnosis of Juvenile Idiopathic Arthritis.Predictors of juvenile idiopathic arthritis course.Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Management of Juvenile Idiopathic Arthritis: A Clinical Guide.In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?Juvenile idiopathic arthritis: management and therapeutic options.Reliability and responsiveness of the Juvenile Arthritis MRI Scoring (JAMRIS) system for the knee.Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.US Evaluation of Juvenile Idiopathic Arthritis and Osteoarticular Infection.Decreasing patient cost and travel time through pediatric rheumatology telemedicine visits.Quantifying Temporomandibular Joint Synovitis in Children With Juvenile Idiopathic Arthritis.[Methotrexate in the therapy of juvenile idiopathic arthritis].Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure.The diagnostic accuracy of unenhanced MRI in the assessment of joint abnormalities in juvenile idiopathic arthritis.Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients.Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study.Confidence amongst Multidisciplinary Professionals in Managing Paediatric Rheumatic Disease in Australia.Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.Genetische Grundlagen der juvenilen idiopathischen Arthritis

P2860

Q26786198-E5A104CF-B43F-4AEA-AF36-19F2CCE7CF13 Q26991741-359FC833-881F-4D89-860E-987097FB18F4 Q26995394-3EF9BB17-74BA-4C91-ACFD-E80ECCBEDA86 Q27001017-C4534674-7C8F-47CB-B65F-A4DF5F36C8A4 Q33697136-660B533D-8D8C-4DDC-8350-3E7C2086084C Q34069374-4608449A-4D21-44BD-917D-2AE6632CF365 Q34185017-E2CCDD5E-DC15-4379-8551-07E55F4D6D25 Q34235121-6A2A5A85-2559-4252-822C-A41433E79E6B Q34580608-716D6EC0-F347-430E-8742-7FC22B8EA50F Q35082782-9BD22BCD-6B69-447C-A942-DBAD15F6A982 Q35567870-516CEADE-F8FC-46F7-A64A-3DD35D6375F2 Q35926593-2BA79808-D004-4803-BFE2-1CF7448911D0 Q36128034-D4A6C629-FFF3-408A-9791-01B38F914CD3 Q36842433-C3993F55-674A-491E-B53C-2BEBA2164D03 Q37006464-FFD30E86-6B17-48EA-B941-C26361AD344E Q37627929-82164F26-92FA-4112-B32D-41481C962B8F Q38214382-C5C344D3-583F-4EB6-8ECC-410A3ABE10F2 Q38223059-AD8D3E9D-C280-4594-879F-B86364F2C6FD Q38238947-42F09F52-EB29-4324-91E0-E5F61C6B9D03 Q38916421-AD9C6C1D-9928-4F6C-A0D9-92CB1F0C9360 Q39210343-6C1A5E17-7EAD-485F-93E7-F8B71D96DB79 Q39243858-EF000FDA-FE03-42F1-BE08-5A17D581BF76 Q39533334-1F7A02AE-D4B4-4205-BC48-A38DB1D7DE43 Q39663220-3383B5D4-190B-4844-A027-48E1D1212EFB Q40139720-40A3A646-632C-4F18-807D-C2DD90569B86 Q41129956-C75F9DD0-9AE0-44CB-ABA6-A3D30C685582 Q41540865-4202DF8A-9B07-424E-ADE4-41B1E2CDF912 Q42969813-ED25F1B1-9700-47A4-9E0E-1F4F581035B1 Q43689633-1819EF33-2B57-46E3-B288-CA42FB72F8E4 Q45828001-62A9613C-2AC6-4B69-B90E-2113D3B1509C Q53113681-8B536A13-28B9-4FF2-BE63-26F0DD2F517B Q54519389-8851F9FA-DBAA-4CBA-8043-53751AD83A65 Q55023560-9697D996-E023-481B-B805-6D2451FFE9FF Q55024382-DA8A8C28-860A-4A1E-8F68-1640CA6AC442 Q55617607-71D723FE-D875-47DD-8DEB-732436656582 Q57956158-E0FDBAF9-13C7-46AC-B2E9-0AD3E921460D

P2860

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

http://www.wikidata.org/entity/Q57788650

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2008

@uk

name

Time to treatment as an import ...... juvenile idiopathic arthritis

@en

Time to treatment as an import ...... juvenile idiopathic arthritis

@nl

type

label

Time to treatment as an import ...... juvenile idiopathic arthritis

@en

Time to treatment as an import ...... juvenile idiopathic arthritis

@nl

prefLabel

Time to treatment as an import ...... juvenile idiopathic arthritis

@en

Time to treatment as an import ...... juvenile idiopathic arthritis

@nl

P1433

Q57788650-C13585E9-C955-4781-839A-A8A9FBDBA070

P1476

Q57788650-E354EB3F-5D22-4627-A27C-17D1708668CD

P2093

Q57788650-02F0ABA2-6FB8-4146-AF24-7398F4D1F482

Q57788650-1AA2E7F7-0A3F-4FBC-9C98-77AB6B1D8567

Q57788650-2C155003-EABD-475F-A397-FAE6D6A3E8B1

Q57788650-2E647040-4654-4174-8850-52BE7DC85B9C

Q57788650-3F511E81-74CF-4DF7-8E44-9BDAC91F5A81

Q57788650-4A0BACC4-9CE3-4F30-AF31-3831BE8F8114

Q57788650-B386E4A0-EA0B-4D85-BFD1-5159F4B12584

Q57788650-B8D341E9-150D-4497-B539-0055EB4CECA1

Q57788650-E77EF157-0194-4A9E-BD07-B54F62A0978F

Q57788650-E78BB042-DE15-4F71-8D7E-2C188C279DB4

P2860

Q57788650-0D407920-3240-4484-9883-BB4EEE481BED

P304

Q57788650-87E555CB-8977-45F9-BE15-E99C326D8E1C

P31

Q57788650-120A4CDA-510E-4609-81F4-EABED87A4C8F

P356

Q57788650-099DE224-19B1-48BD-A0FF-B5BF292A4B34

P433

Q57788650-DF55871A-53C5-45F0-B4C1-0C5B3C97772E

P478

Q57788650-D948BF6D-68AC-4E27-9BE6-2386E7925FD9

P50

Q57788650-241CDEAC-BBB9-4FE1-BC3D-BA1D35495F0F

Q57788650-9BEBB113-F412-439F-8E76-E4FFB5D07765

Q57788650-AA0ED823-A12A-4236-866C-867DC25E71D8

P577

Q57788650-9EE5CD8C-2A8C-473D-ADD8-44C7FB767910

P698

Q57788650-1B5ACB3F-8DCB-4766-B24E-A356B7608D80

P921

Q57788650-199BF22E-588C-48B9-8F0B-B90FEAFA6CD1

Q57788650-94EFC3F2-BCBA-4A89-912B-2EADD0982698

Q57788650-A9858D0E-BE8F-4026-B489-D5E54C6CCD80

P356

P1433

Arthritis and Rheumatism

P1476

Time to treatment as an import ...... juvenile idiopathic arthritis

@en

P2093

D M C Brinkman

http://www.w3.org/2001/XMLSchema#string

H J Girschick

http://www.w3.org/2001/XMLSchema#string

H M Albers

http://www.w3.org/2001/XMLSchema#string

J A M Wessels

http://www.w3.org/2001/XMLSchema#string

L W A Suijlekom-Smit

http://www.w3.org/2001/XMLSchema#string

M W Schilham

http://www.w3.org/2001/XMLSchema#string

R J H M van der Straaten

http://www.w3.org/2001/XMLSchema#string

R Ten Cate

http://www.w3.org/2001/XMLSchema#string

S S M Kamphuis

http://www.w3.org/2001/XMLSchema#string

T W J Huizinga

http://www.w3.org/2001/XMLSchema#string

P2860

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.

P304

46-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.24087

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Saskia le Cessie

Henk-Jan Guchelaar

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19116975

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis